Drugs / LUVIXASERTIB
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02792465 | Nov 2016 → Jun 2025 | breast cancer | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05251714 | May 2022 → Aug 2026 overdue | breast cancer | Treadwell Therapeutics, Inc | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03568422 | Feb 2019 → Nov 2022 overdue | breast cancer | Canadian Cancer Trials Group | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05601440 | Jun 2023 → Dec 2027 expected | female breast carcinoma | Canadian Cancer Trials Group | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LUVIXASERTIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4469414 ↗ |
| Known as | CFI-402257 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05601440 ↗ |
| Known as | CPD 24 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4469414 ↗ |
| Action | Inhibit | “blocks TTK protein kinase” NCT02792465 ↗ |
| Modality | Small molecule | — CHEMBL4469414 ↗ |
| Route | Oral | “CFI-402257 capsules will be taken orally, once a day, every day.” NCT02792465 ↗ |
| Target | TTK | “blocks TTK protein kinase” NCT02792465 ↗ |